Nosological classification (ICD-10)
Description of the dosage form
Tablets, 10 mg. Truncated-oval, biconvex, pale pink in color with a risk on one side.
Tablets, 15 mg. Round, flat, pale yellow color, with a facet.
Tablets, 30 mg: Round, biconvex, pale pink color.
The therapeutic effect of aripiprazole in schizophrenia and type 1 bipolar disorder is assumed to be due to a combination of partial agonistic activity against D2-dopamine and 5HT1a-serotonin receptors and antagonistic activity against 5HT2a-serotonin receptors. Aripiprazole in animal experiments showed antagonism in relation to dopaminergic hyperactivity and agonism in relation to dopaminergic hypoactivity. Aripiprazole possesses high in vitro affinity for D2 and D3 dopamine receptors, 5HT1a and 5HT2a serotonin receptors, and moderate affinity for D4 dopamine, 5HT2c and 5HT7 serotonin receptors, and α1 adrenoreceptrs, and I and adrenoreceptors and I and I systems. Aripiprazole is also characterized by moderate affinity for serotonin reuptake sites and lack of affinity for m-cholinergic receptors. Some of the clinical effects of aripiprazole may be attributed to the interaction with receptors other than dopamine and serotonin.
When aripiprazole is administered orally in healthy volunteers at a dose of